Clinical Trial: A Study of DA-302168S in Participants With Overweight/Obesity

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07629544) titled 'A Study of DA-302168S in Participants With Overweight/Obesity' on May 27.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.

Study Start Date: June 27

Study Type: INTERVENTIONAL

Condition: Overweight and Obesity

Intervention: DRUG: DA-302168S

A small molecule GLP-1R agonist tablet, orally administration, once daily

DRUG: DA-302168S

A small molecule GLP-1R agonist tablet, orally administration, once daily

DRUG: Pla...